Blood thinners for liver vein clot in cirrhosis
Treatments studied
Part of Digestive system clinical trials.
This trial tests whether a pill (dabigatran) or a daily injection (enoxaparin) is better at preventing new blood clots in the liver vein for people with cirrhosis. Both are blood thinners, and the study wants to see which one is safer and more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are over 18 years old.
- You have cirrhosis and a recent blood clot in the portal vein (the main vein to the liver) — either newly found, causing symptoms, or found during a transplant evaluation.
- You are not currently bleeding, and you do not have conditions that make blood thinners risky (like recent major surgery or allergy to the study drugs).
- Your liver function is not too severely impaired (scoring above 10 on a standard liver test is excluded).
- You do not have liver cancer (hepatocellular carcinoma) or a clot caused by a tumor.
- Your kidney function is adequate: no acute kidney injury and no advanced chronic kidney disease (stage 4 or 5).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether blood thinners (anticoagulants) are safe and effective for people with cirrhosis and a blood clot in the portal vein. It may also include people with liver cancer (HCC).
This study is following people with cirrhosis to see how often they get a blood clot in the liver's main vein (portal vein) and whether using blood thinners helps. If you have cirrhosis, joining this study could help doctors learn better ways to prevent and treat these clots.
This trial tests a new oral blood thinner to prevent another bleeding episode in people with liver cirrhosis who have already had variceal bleeding and also have a clot in the portal vein. The goal is to see if it can safely reduce the risk of rebleeding.
This early study tests whether the blood thinner pills rivaroxaban and apixaban can be used safely in people with liver cirrhosis that is not too severe. It may help doctors understand the safest way to prevent or treat blood clots in this group.
This study tests whether a blood thinner called apixaban can safely prevent dangerous bleeding in people with cirrhosis (liver scarring) who have portal hypertension (high blood pressure in veins leading to the liver). The goal is to see if it reduces bleeding risk without causing excessive bleeding.
This Phase 2 study tests a blood-thinner called a DOAC in people with previously diagnosed mild or moderate liver cirrhosis (Child A or B). It may help doctors understand whether the medicine is safe and effective in this group.
Hear when a new Portal Vein Thrombosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.